<DOC>
	<DOC>NCT00663052</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.</brief_summary>
	<brief_title>Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 years of age or older at time of consent. Active, moderate to severe chronic plaque psoriasis defined by the following criteria: Clinically stable, plaque psoriasis involving greater than or equal to 10% body surface area (BSA) or PASI greater than or equal to 10. In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following: Methotrexate (MTX), cyclosporine and psoralen plus ultraviolet A radiation (PUVA) therapy. Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis. Rheumatologic disease such as rheumatoid arthritis, systemic lupus erythematous, systemic vasculitis, scleroderma and polymyositis, or associated syndromes. Active or recent (within 2 years) tuberculosis (TB) infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Enbrel</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Topical Psoriasis</keyword>
	<keyword>Wyeth Psoriasis</keyword>
	<keyword>Active Psoriasis</keyword>
</DOC>